Navigation Links
Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Date:3/7/2008

LAUSANNE, Switzerland, March 7 /PRNewswire/ -- Galderma Pharma, S.A. announces an agreement with ZARS Pharma, Inc. giving Galderma exclusive rights for all markets outside the USA and Canada for promotion and distribution of a novel topical anesthetic cream. This partnership follows an agreement signed last year between Galderma and ZARS Pharma for the promotion and distribution of Pliaglis(TM) in the USA and Canada.

"This agreement gives us a new opportunity to contribute to progress in patient care worldwide," said Humberto C. Antunes, CEO of Galderma. "As the market for corrective and aesthetic procedures continues to grow, Pliaglis(TM), with its unique vehicle and comfort of use for both patient and doctor is poised to fill an important unmet need. This agreement is part of our strategy to offer a comprehensive range of products that improve corrective and aesthetic procedural outcomes and complement our current family of therapeutic Rx and OTC products throughout the world."

Pliaglis(TM) (lidocaine and tetracaine) Cream 7%/7% is the first FDA-approved prescription-strength lidocaine and tetracaine combination topical anesthetic cream indicated to provide topical local analgesia for superficial dermatological procedures such as, among others, dermal filler injections, facial laser resurfacing and laser-assisted tattoo removal.

Formulated in a unique cream vehicle, Pliaglis(TM) is easily applied to the skin and forms a pliable self-occlusive mask which is easily peeled off the skin prior to a procedure. Pliaglis(TM) is a versatile new tool for use in many of the most common corrective and aesthetic procedures. With proven clinical efficacy, a unique phase-changing vehicle and an onset of action between 20-30 minutes, Pliaglis(TM) represents a technological innovation in patient's comfort.

"We are convinced that Pliaglis(TM) will be very well received by dermatologists and other physicians in Europe and Asia," said Francois Fourn
'/>"/>

SOURCE Galderma Pharma, S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
2. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
3. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
4. TyRx Pharma, Inc. Announces Presentation of Results to Benefit Women with Breast Implants (In-Vivo Efficacy Study Regarding AIGISRx DEB) at the Plastic Surgery 2007 Meeting on October, 28 2007 in Baltimore, MD
5. GeoPharma, Inc. to Present at the EdgeWater Research Investor Conference
6. FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX(TM)
7. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
8. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
9. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
10. Actavis Extends Portfolio With Four New Products in the U.S.
11. CDC Panel Urges Extending Flu Vaccine Coverage for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 Specialty ... in Westlake, OH, announces that they have achieved ... PowerServer, a Complete Certified Ambulatory EHR-certified system developed ... Specialty Teleradiology had a non MU compliant PACS ... their business grew from a niche in oncology ...
(Date:9/18/2014)... Doylestown, PA (PRWEB) September 18, 2014 ... month by successfully launching its first product a mere ... F PRIME™ is a high performance glycan release enzyme ... assurance, glycobiology research, and the basis for tissue pathology ... Bulldog Bio (Portsmouth, NH) for the North American market ...
(Date:9/18/2014)... 9Lover.com, an internationally well-known designer and leader in ... promotion for its maternity wedding outfits. Now, all the ... maternity wedding dresses on its website. , ... consumers. The company’s development manager believes the cheap maternity ... The current special offer will last until September 29, ...
(Date:9/17/2014)... 2014 Today, Fecbek, a leading dress manufacturer ... special occasion gowns. These are a lot of beautiful A-line ... new range. , A skirt is a tube- or ... or part of the legs. In the western world, skirts ... be a draped garment which is made out of a ...
(Date:9/17/2014)... Recently, UWDress.com, an innovative company that ... occasion outfits, has released its 2014 empire waist ... has launched a big sale for these new and ... deeply discounted rates, from 15 to 65 percent off. ... on using comfortable to wear materials. Its elegant items ...
Breaking Medicine News(10 mins):Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:Fecbek.com Has Recently Announced Its New Series of Delicate Special Occasion Gowns Online 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2
... Sweden: Two trials presented at the Heart Failure Congress 2011, ... European Society of Cardiology (HFA of the ESC), will help ... heart failure (CHF) in whom telemedical management delivers benefits. ... Late Breaking Session 1 - revealed that telemonitoring showed significant ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, ... benefits of robotic surgery on their websites without solid ... researchers report. In fact, four out of 10 ... robotic surgery is better than conventional surgery, an assertion ...
... May 21 (HealthDay News) -- As summer approaches and ... experts say. "We are not invincible when it ... an athletic trainer with the University of Tennessee at ... Medical and Science Advisory Board, in a news release ...
... chemotherapy is used to kill cancer cells, it can also ... bone marrow and blood cells, often limiting the ability to ... Cancer Research Center reported at today,s annual meeting of the ... one possible approach to reduce this toxic effect on bone ...
... York, NY (May 20, 2011)The American Federation for Aging Research ... 83 advanced fellows and junior faculty at 27 Centers of ... This effort, funded with support from the John A. Hartford ... create the cadre of academic leaders in geriatrics. As our ...
... , FRIDAY, May 20 (HealthDay News) -- Treating chronic ... and function, according to a new study. Prior research ... problems and reduced gray matter in brain areas that play ... pain, such as anxiety and depression. But it wasn,t clear ...
Cached Medicine News:Health News:Telemonitoring can improve overall survival of HF patients 2Health News:Telemonitoring can improve overall survival of HF patients 3Health News:Telemonitoring can improve overall survival of HF patients 4Health News:Telemonitoring can improve overall survival of HF patients 5Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 2Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 3Health News:Robotic Surgery Oversold on Hospital Websites, Study Contends 4Health News:Keeping Cool in the Heat 2Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:AFAR announces the 2011 Hartford Scholars in Geriatric Medicine 2
(Date:9/17/2014)... -- According to a new market research ... Device, Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... reach $56.50 Billion by 2020, growing at a CAGR ... 235 market data Tables and 71 Figures spread through ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
100cc silicone evacuator with hubless flat drain and trocar...
Used following open gallbladder procedure to drain bile. Often attached to Bard bile bag....
Silicone Flat Hubless Drains...
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Medicine Products: